Author + information
- Received October 22, 2017
- Revision received January 26, 2018
- Accepted February 13, 2018
- Published online April 16, 2018.
- Salman Razvi, MDa,b,∗ (, )
- Avais Jabbar, MDa,c,
- Alessandro Pingitore, MDd,
- Sara Danzi, PhDe,
- Bernadette Biondi, MDf,
- Irwin Klein, MDg,
- Robin Peeters, MDh,
- Azfar Zaman, MDc,i and
- Giorgio Iervasi, MDd
- aInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- bGateshead Health NHS Foundation Trust, Gateshead, United Kingdom
- cFreeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
- dClinical Physiology Institute, Consiglio Nazionale dele Ricerche (CNR), Pisa, Italy
- eQueensborough Community College, The City University of New York, Bayside, New York
- fDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
- gSchool of Medicine, New York University, New York, New York
- hDepartment of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus Medical Centre, Rotterdam, the Netherlands
- iInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- ↵∗Address for correspondence:
Dr. Salman Razvi, Institute of Genetic Medicine, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom.
Thyroid hormone (TH) receptors are present in the myocardium and vascular tissue, and minor alterations in TH concentration can affect cardiovascular (CV) physiology. The potential mechanisms that link CV disease with thyroid dysfunction are endothelial dysfunction, changes in blood pressure, myocardial systolic and diastolic dysfunction, and dyslipidemia. In addition, cardiac disease itself may lead to alterations in TH concentrations (notably, low triiodothyronine syndrome) that are associated with higher morbidity and mortality. Experimental data and small clinical trials have suggested a beneficial role of TH in ameliorating CV disease. The aim of this review is to provide clinicians dealing with CV conditions with an overview of the current knowledge of TH perturbations in CV disease.
Dr. Razvi has received speaker fees from Merck KGaA and EXCEMED. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received October 22, 2017.
- Revision received January 26, 2018.
- Accepted February 13, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.